This guest post from Sue Jinks-Robertson describes a personal experience with the NIGMS MIRA program. If you wish to share your perspective on MIRA or any other topic of interest to the GSA community, please consider authoring a guest post; send your ideas to blog@genetics-gsa.org.

 

Contributed by guest author Sue Jinks-Robertson

I’ve been on the grant roller coaster at NIGMS (GM) since 1989, and in the past five years, have fluctuated between one and three small (<$200,000) grants; the average has been ~2.25 grants per year.  Given the almost certain lapses in funding between grant cycles, this level of support was enough to run a small lab of about six.  Needless to say, I was thrilled when the call for Maximizing Investigators’ Research Awards (MIRAs) was announced early last year and was eager to sign up. The prospect of funding stability, flexibility to pursue new research directions, and less time spent writing grant proposals was very appealing, even with the likelihood that “in general, the amount of a MIRA award will be somewhat less that the sum of all recent NIGMS support.” I should have remembered the old adage, “if something seems too good to be true, it probably is.”

Each of us who applied for a MIRA was in different situation in terms of grant cycles and the availability of non-GM support, and I’ll focus on my own particular situation.  Some investigators are much better off than I am and are happy with the MIRA outcome, and some are in a worse situation. In my case, all of the support for my lab comes from GM: two grants went into a no-cost extension in summer 2014 and a third expires at the end of April. I staggered the competing renewals (each had previously gone to the same Study Section) and as seems to be the norm these days, neither competitive renewal scored in the funding range the first time through. Funding was restored for the first grant in summer 2015, but both the revision for grant #2 and the competing renewal for grant #3 had to be put on hold with the MIRA submission in May 2015. Since MIRAs are intended to replace all GM funding, “applications that overlap scientifically cannot be in review at the same time.”

The MIRA applications were reviewed in October 2015, but neither funding decisions nor funding levels were available until mid-February 2016. By that time, it was too late to submit any revisions/competing renewals for the spring deadline. The good news is that I was awarded a MIRA; the bad news is that the budget is the equivalent of ~1.7 of my small grants. That translates into a “non-negotiable” 25% cut in my average funding level over the past 4–5 years. I’ve heard anecdotally that budget cuts range from 12–50%, and my attempts (to understand how funding levels were determined has been unsuccessful. Some labs can absorb the budget cuts, while others will be forced to reduce personnel. As all of my support has been from GM, I’m squarely in the latter category.

So, what will the MIRA do for me? It will give me some stability, as advertised, but instead of a lab of ~6 supported by GM, I now can afford a lab of 2–3. While some may say this is consistent with the promise of “somewhat less support,” it’s actually a severe disruption for my program and will result in a forced downsizing. Being in a Medical School, I’m still expected to recover at least 50% of my salary, so a budget cut directly translates into reduced personnel. What really bothers me the most about the whole process is that I’ve been painted into a corner by the policies and procedures of the first round of MIRA funding. If I turn the MIRA down, I’ll be facing at least a year of running off a single, small R01. If I accept the MIRA, I’ll be left scrambling for additional support outside of GM, which means the promised respite from writing proposals has evaporated. Whether any of the programmatic themes included in the MIRA application can even be used as the basis for a grant elsewhere within the NIH is unclear.

Although several changes have been made in the latest MIRA announcement, they do nothing for me. The institution of the one-grant MIRA model and its associated budget cuts is “mission accomplished” for GM: more researchers can be supported as MIRA recipients are forced to look elsewhere for funding.  To others who may be considering putting in a MIRA application, I hope you can learn from my experience.  In the end, I had no viable option other than to accept the MIRA and try to move forward.

 

 

Sue Jinks-Robertson, PhD, is Professor of Molecular Genetics and Microbiology and director of the Cell and Molecular Biology Program at Duke University School of Medicine, where she uses S. cerevisiae to study the pathways that regulate mitotic genome stability. She currently serves as GSA Treasurer.

 

The views expressed in guest posts are those of the author and are not necessarily endorsed by the Genetics Society of America.

, ,

Guest posts are contributed by members of our community. The views expressed in guest posts are those of the author(s) and are not necessarily endorsed by the Genetics Society of America. If you'd like to write a guest post, e-mail communications@genetics-gsa.org.

View all posts by Guest Author »

Read more in

  • Ed Grell at his dissecting microscope using ether to anesthetize his flies.

    In Memoriam: Ellsworth Herman Grell (1932–2023), a pioneer of Drosophila genome engineering and annotation

    Ellsworth (Ed) Grell blessed the Drosophila community through three enduring legacies: as a pioneer of chromosome mechanics, as a primary organizer and synthesizer of genetic knowledge in Drosophila, and as a graceful mentor to those fortunate to have known him personally. Ed grew up in rural Nebraska, completed his undergraduate studies at Iowa State, and…

  • Congratulations to the #Fungal24 Poster Award winners!

    We are pleased to announce the recipients of the GSA Poster Awards for posters presented at the 32nd Fungal Genetics Conference! Undergraduate and graduate student members of GSA were eligible for the awards, and a hard-working team of judges made the determinations. Congratulations to all! Felicia Ebot Ojong, The University of Georgia My research is focused…

  • Poster presentation tips for TAGC 2024

    You’ve been selected to present a poster at The Allied Genetics Conference 2024 in March—you’ve celebrated, made plans to attend, now what? This is an exciting opportunity to showcase your research and engage with fellow members of the genetics community, so you want to make sure you’re prepared. We wanted to offer you some tips…

  • Maximize your TAGC 2024 experience 

    A guide to all that National Harbor & DC have to offer Are you joining us for The Allied Genetics Conference 2024 in March? Make the most of your #TAGC24 experience in National Harbor! We know the science will keep you busy, but you deserve to unwind and have some fun, so we’ve curated a…

  • Early Career Leadership Spotlight: Sarah Petrosky

    We’re taking time to get to know the members of the GSA’s Early Career Scientist Committees. Join us to learn more about our early career scientist advocates. Sarah PetroskyMultimedia SubcommitteeUniversity of Pittsburgh Research Interest I am interested in understanding adaptation that has been happening recently in populations by dissecting the ways that genes underlying an adaptation…

  • TAGC 2024 Early Career Award Winners

    GSA is pleased to announce the winners of the early career awards presented at The Allied Genetics Conference 2024. These awards are specific to particular TAGC communities and recognize early career scientists’ outstanding work on their respective research organisms. The awardees will present their talks in keynote sessions at TAGC 2024.  Don’t miss the opportunity…

  • Preeminent geneticists recognized with revamped GSA Awards

    In 2022, GSA’s Board of Directors launched an audit to review the five major awards conferred by the Society. Today, we are thrilled to announce the recipients of the reimagined GSA Awards, including the new Genetics Society of America Early Career Medal. The scientists honored this year are recognized by their peers for their outstanding…

  • Fly Board funds outreach programs to spread the word about Drosophila research

    In 2020, the Fly Board voted to use part of its reserve fund to support efforts to increase trainee participation as well as equity and diversity in the Drosophila community. An awards committee decides how the money will be spent each year, and from 2020–2022, the committee posted a very broad call for applications from…

  • New members of the GSA Board of Directors: 2024–2026

    We are pleased to announce the election of four new leaders to the GSA Board of Directors: 2024 Vice President/2025 President Brenda Andrews Professor, University of Toronto It’s an honor to continue my association with the Society by serving as Vice President of the Board of Directors. I have broad knowledge of the ongoing activities…

  • A rose-ringed parakeet, one of three parrot species used in the study.

    Parrot plumage study aids breeders and endangered natural populations

    Yellow coloration is maladaptive in the wild but prized by breeders. People have long been fascinated with birds, which exhibit one of the widest ranges of coloration among vertebrates. Parrots, in particular, have captivated humans by their ability to mimic human speech and spectacular plumage. Brightly colored feathers are used primarily to attract mates, intimidate…

  • Early Career Leadership Spotlight: Sarah Gilmour

    We’re taking time to get to know the members of the GSA’s Early Career Scientist Committees. Join us to learn more about our early career scientist advocates. Sarah GilmourMultimedia SubcommitteeStowers Institute for Medical Research Research Interest Questions of evolution have always fascinated me. I am extremely fortunate to be starting out my research career in a…